Vagal changes following cancer chemotherapy: Implications for the development of nausea

Psychophysiology

Volumn 37, Issue 3, 2000, Pages 378-384

  Morrow, Gary R ^a,d   Andrews, Paul L R ^b   Hickok, Jane T ^a   Stern, Robert ^c  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c PENNSYLVANIA STATE UNIVERSITY   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Autonomic nervous system; Cancer; Chemotherapy; Heart rate variability; Nausea; Parasympathetic nervous system

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; METOCLOPRAMIDE; PROCHLORPERAZINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; FEMALE; HEART RATE VARIABILITY; HUMAN; NAUSEA; OVARY CANCER; PARASYMPATHETIC INNERVATION; PRIORITY JOURNAL; VAGUS NERVE;

EID: 0034129934     PISSN: 00485772     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0048577200981952     Document Type: Article

References (58)

1. Andrews, P. L., Rapeport, W. G., & Sanger, G. J. (1988). Neuropharmacology of emesis induced by anti-cancer therapy. Trends in Pharmacological Sciences, 9, 334-341.
2. Andrews, P. L. R. (1996). The mechanism of emesis induced by chemotherapy and radiotherapy. In M. Tonato (Ed.), Antiemetics in the supportive care of cancer patients (pp. 3-24). Heidelberg, Germany: Springer-Verlag.
3. Andrews, P. L. R., & Davis, C. J. (1993). The mechanisms of emes:s induced by anti-cancer therapies. In P. L. R. Andrews & C. J. Sanger (Eds.), Emesis in anti-cancer therapy (pp. 113-163). London: Chapman & Hall.
4. Andrews, P. L. R., & Davis, C. J. (1995). The physiology of emesis induced by anti-cancer therapy. In D. J. M. Reynolds, P. L. R. Andrews, & C. J. Davis (Eds.), Serotonin and the scientific basis of anti-emetic therapy (pp. 25-49). Oxford, UK: Oxford Clinical Communications.
5. Bellg, A. J., Morrow, G. R., Barry, M., Angel, C., & DuBeshter, B. (1995). Autonomic measures associated with chemotherapy-related nausea: Techniques and issues. Cancer Investigation, 13, 313-323.
6. Carr, B., Pulone, B., Bertrand, M., Browning, S., Doroshow, J., Klein, L., Presant, C., Chang, F., Carr, B. I., Doroshow, J. H., Present, A. N. T. C., & Hill, R. L. (1985). A comparison of the antiemetic efficacy of prochlorperazine and metoclopramide for the treatment of cisplatin induced emesis: A prospective, randomized, double-blind study. Journal of Clinical Oncology, 3, 1127-1132.
7. Coates, A., Abraham, S., Kaye, S. B., Sowerbutts, T., Frewin, C., Fox, R. M., & Tattersall, M. H. (1983). On the receiving end - Patient perception of the side-effects of cancer chemotherapy. European Journal of Cancer and Clinical Oncology, 19, 203-208.
8. Cohen, J. (1987). Statistical power analysis for the behavioral sciences. New York: Academic Press.
9. Cowings, P. S., Suter, S., Toscano, W. B., Kamiya, J., & Naifeh, K. (1986). General autonomic components of motion sickness. Psychophysiology, 23, 542-551.
10. Cull, A. (1993). Psychological effects of anti-cancer therapy. In P. L. R. Andrews & G. J. Sanger (Eds.), Emesis in anti-cancer therapy. Mechanisms and treatment (pp. 211-228). London: Chapman & Hall.
11. Davis, C. J., Harding, R. K., Leslie, R. A., & Andrews, P. L. R. (1986). The organization of vomiting as a protective reflex. In C. J. Davis, G. V. Lake-Bakaar, & D. G. Grahame-Smith (Eds.), Nausea and vomiting: Mechanism and treatment (pp. 65-78). Berlin, Germany: Springer-Verlag.
12. de Mulder, P. H. M., Seynaeve, C., Vermorken, J. D., van Liessum, P. A., Mols-Jevdevic, S., Allman, E. L., Beranek, P., & Verweij, J. (1990). Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Annals of Internal Medicine, 113, 834-840.
13. du Bois, A. (1998). Platinum-induced delayed emesis. In M. Dicato (Ed.), Medical management of cancer treatment induced emesis. (pp. 71-85). London: Martin Dunitz Ltd.
14. Feyer, P., & Titlbach, O. J. (1998). Treatment of radiotherapy-induced nausea and vomiting. In M. Dicato (Ed.), Medical management of cancer treatment induced emesis (pp. 103-129). London: Martin Dunitz.
15. Fox, R. A. (1992). Current status: Animal models of nausea. In A. L. Bianchi, L. Grelot, A. D. Miller, & G. L. King (Eds.), Mechanisms and control of emesis (pp. 341-350). London: Colloque INSERM/John Libbey Eurotext.
16. Fredrikson, M., Hursti, T., Salmi, P., Borjeson, S., Furst, C. J., Peterson, C., & Steineck, G. (1993). Conditioned nausea after cancer chemotherapy and autonomic nervous system conditionability. Scandinavian Journal of Psychology, 34, 318-327.
17. Harding, R. K. (1990). Concepts and conflicts in the mechanism of emesis. Canadian Journal of Physiology and Pharmacology, 68, 218.
18. Harding, R. K., Young, R. W., & Anno, G. H. (1993). Radiotherapy-induced emesis. In P. L. R. Andrews & G. J. Sanger (Eds.), Emesis in anti-cancer therapy: Mechanisms and treatment (pp. 163-178). London: Chapman and Hall.
19. Hesketh, P. J. (1992). Comparative trials of ondansetron versus metoclopramide in the prevention of acute cisplatin-induced emesis. Seminars in Oncology, 19, 33-40.
20. Hu, S., Grant, W. R. Stern, R. M., & Koch, K. L. (1991). Motion sickness severity and physiological correlates during repeated exposures to a rotating optokinetic drum. Aviation Space and Environmental Medicine, 62, 308-314.
21. Isaacs, B. (1957). The influence of head and body positions on the emetic action of apomorphine in man. Clinical Science. 16, 215-221.
22. Jantunen, I. T., Flander, M. K., Heikkinen, M. I., Kuoppala, T. A., Teerenhovi, L., & Kataja, V. V. (1993). Comparison of ondansetron with customary treatment in the prophylaxis of nausea and emesis induced by non-cisplatin containing chemotherapy. Acta Oncologica, 32, 413-415.
23. Koch, K. L., Stern, R. M., Vasey, M., Botti, J. J., Creasy, G. W., & Dwyer, A. (1990a). Gastric dysrhythmias and nausea of pregnancy. Digestive Diseases and Sciences, 35, 961-968.
24. Koch, K. L., Summy-Long, J., Sperry, N., & Stern, R. M. (1990b). Vasopressin and oxytocin responses to illusory self-motion and nausea in man. Journal of Clinical Endocrinology and Metabolism, 71, 1269-1275.
25. Kris, M. G., Grunberg, S. M., Gralla, R. J., Baltzer, L., Zaretsky, S. A., Lifsey, D., Tyson, L. B., Schmidt, L., & Hahne, W. F. (1994). Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. Journal of Clinical Oncology, 12, 1045-1049.
26. Kvale, G., & Hugdahl, K. (1994). Cardiovascular conditioning and anticipatory nausea and vomiting in cancer patients. Behavioral Medicine, 20, 78-83.
27. Kvale, G., Hugdahl, K., Asbjornsen, A., Rosengren, B., Lote, K., & Nordby, H. (1991). Anticipatory nausea and vomiting in cancer patients. Journal of Consulting and Clinical Psychology, 59, 894-898.
28. Latreille, J., Pater, J., Johnston, D., Laberge, F., Stewart, D., Rusthoven, J., Hoskins, P., Findlay, B., McMurtrie, E., Yelle, L., Williams, C., Walde, D., Ernst, S., Dhaliwal, H., Warr, D., Shepherd, F., Mee, D., Nishimura, L., Osoba, D., & Zee, B. (1998). Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. Journal of Clinical Oncology, 16, 1174-1178.
29. Love, R. R., Leventhal, H., Easterling, D. V., & Nerenz, D. R. (1989). Side effects and emotional distress during cancer chemotherapy. Cancer, 63, 604-612.
30. Miller, J. C., Sharkey, T. J., Graham, G. A., & McCauley, M. E. (1993). Autonomic physiological data associated with simulator discomfort. Aviation Space and Environmental Medicine, 64, 813-819.
31. Minton, N. A., Glucksman, E., & Henry, J. A. (1995). Prevention of drug absorption in simulated theophylline overdose. Human and Experimental Toxicology, 14, 170-174.
32. Morrow, G. R. (1984a). Clinical characteristics associated with the development of anticipatory nausea and vomiting in cancer patients under-going chemotherapy treatment. Journal of Clinical Oncology, 2, 1170-1176.
33. Morrow, G. R. (1984b). Susceptibility to motion sickness and chemotherapy-induced side effects [Letter]. Lancet, 1, 390-391.
34. Morrow, G. R. (1984c). Susceptibility to motion sickness and the development of anticipatory nausea and vomiting in cancer patients under-going chemotherapy. Cancer Treatment Reports, 68, 1177-1178.
35. Morrow, G. R. (1984d). The assessment of nausea and vomiting: Past problems, current issues, and suggestions for future research. Cancer. 53, 2267-2278.
36. Morrow, G. R. (1985). The effect of a susceptibility to motion sickness on the side effects of cancer chemotherapy. Cancer. 55, 2766-2770.
37. Morrow, G. R., Angel, C., & DuBeshter, B. (1992). Autonomic changes during cancer chemotherapy induced nausea and emesis. British Journal of Cancer, 19(Suppl.), S42-S45.
38. Morrow, G. R., Arseneau, J. C., Asbury, R. F., Bennett, J. M., & Boros, L. (1982). Anticipatory nausea and vomiting with chemotherapy. New England Journal of Medicine, 306, 431-432.
39. Morrow, G. R., & Dobkin, P. L. (1987). Behavioral approaches for the management of adversive side effects of cancer treatment [Review]. Psychiatric Medicine, 5, 299-314.
40. Morrow, G. R., & Dobkin, P. L. (1988). Anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment: Prevalence, etiology, and behavioral interventions. Clinical Psychology Review, 8, 517-556.
41. Morrow, G. R., Hickok, J. T., Burish, T. G., & Rosenthal, S. N. (1996). Frequency and clinical implications of delayed nausea and delayed emesis. American Journal of Clinical Oncology, 19, 199-203.
42. Morrow, G. R., Hickok, J. T., & Rosenthal, S. N. (1995). Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril) and tropisetron (Navoban). Cancer, 76, 343-357.
43. Morrow, G. R., Lindke, J., & Black, P. (1992). Measurement of quality of life in patients: Psychometric analyses of the Functional Living Index-Cancer (FLIC). Quality of Life Research, 1, 287-296.
44. Morrow, G. R., Lindke, J., & Black, P. M. (1991a). Anticipatory nausea development in cancer patients: Replication and extension of a learning model. British Journal of Psychology, 82, 61-72.
45. Morrow, G. R., Lindke, J., & Black, P. M. (1991b). Predicting development of anticipatory nausea in cancer patients: Prospective examination of eight clinical characteristics. Journal of Pain and Symptom Management, 6, 215-223.
46. Morrow, G. R., & Rosenthal, S. N. (1996). Models, mechanisms and management of anticipatory nausea and emesis [Review]. Oncology, 53(Suppl. 1), 4-7.
47. Muth, E. R., Stern, R. M., & Koch, K. L. (1994). Effects of vection-induced motion sickness on skin conductance, blood pressure, respiratory sinus arrhythmia and gastric myoelectric activity [Abstract]. Psychophysiology, 37(Suppl.), S71.
48. Navari, R. M., Gandara, D. R., Hesketh, P. J., Hall, S., Mailliard, J., Ritter, H., Friedman, C., & Fitts, D. (1995). Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. Journal of Clinical Oncology, 13, 1242-1248.
49. Navari, R. M., Kaplan, H. G., Gralla, R. J., Grunberg, S. M., Palmer, R., & Fitts, D. (1994). Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. Journal of Clinical Oncology, 12, 2204-2210.
50. Seymour, M. T. (1993). The pharmacokinetics and pharmacodynamics of chemotherapeutic agents. In P. L. R. Andrews & C. J. Sanger (Eds.), Emesis in anti-cancer therapy (pp. 9-45). London: Chapman & Hall.
51. Soukop, M. (1998). Platinum-induced acute nausea and vomiting. In M. Dicato (Ed.). Medical management of cancer treatment induced emesis (pp. 55-69). London: Martin Dunitz.
52. Stern, R. M., Koch, K. L., Stewart, W. R., & Lindblad, I. M. (1987). Spectral analysis of Tachygastria recorded during motion sickness. Gastroenterology, 92, 92-97.
53. Stewart, A., McQuade, B., Cronje, J. D. E., Goedhals, L., Gudgeon, A., Corette, L., Froger, X., Tubiana-Hulin, M., Laplaige, P., Roberts, J. T., McRae, J., Forster, J., Parasuraman, T. V., & Butcher, M. (1995). Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: A multicentre, double-blind, double-dummy, randomized, parallel-group study. Oncology, 52, 202-210.
54. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. (1996). Heart rate variability: Standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology [see comments]. Circulation, 93, 1043-1065.
55. Uijtdehaage, S. H. J., Stern, R. M., & Koch, K. L. (1992). Effects of eating on vection-induced motion sickness, cardiac vagal tone, and gastric myoelectric activity. Psychopathology, 29, 193-201.
56. Uijtdehaage, S. H. J., Stern, R. M., & Koch, K. L. (1993). Effects of scopolamine on autonomic profiles underlying motion sickness susceptibility. Aviation Space and Environmental Medicine, 64, 1-8.
57. Voliotis, D. L., & Diehl, V. (1998). Clinical aspects and prognostic factors of nausea and vomiting after chemotherapy. In M. Dicato (Ed.), Medical management of cancer treatment induced emesis (pp. 45-54). London: Martin Dunitz.
58. Wilcox, P. M., Fetting, J. H., Nettesheim, K. M., & Abeloff, M. D. (1982). Anticipatory vomiting in women receiving cyclophosphamide, niethotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma. Cancer Treatment Reports, 66, 1601-1604.